NCT03588039View on ClinicalTrials.gov

Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

October 25, 2018

Primary Completion Date

May 12, 2023

Study Completion Date

May 12, 2023

Conditions
Solid Tumor
Interventions
DRUG

Oraxol

Oral paclitaxel will be supplied in capsules and oral HM30181AK-US will be supplied in tablets

BIOLOGICAL

Pembrolizumab

Intravenously administered

Trial Locations (4)

32224

Mayo Clinic, Jacksonville

48201

Karmanos Cancer Institute, Detroit

55905

Mayo Clinic, Rochester

85054

Mayo Clinic, Phoenix

Sponsors

Lead Sponsor

Athenex, Inc.
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Athenex, Inc.

INDUSTRY